TEVA Stock Climbs as 50-Year-Long Tourette Syndrome Drug Breakthrough Moves Closer
Shares in Teva Pharmaceutical Industries ($TEVA) were healthier today after a potential 50-year-long breakthrough treatment for Tourette syndrome m...
Teva Pharmaceutical Industries Ltd (TEVA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Rubric Capital Management David Rosen | 15,575,000 | $527,681,000 | +3% | 4.84% |
| 2. | Alyeska Investment Group Anand Parekh | 6,257,579 | $212,006,777 | +14% | 0.55% |
| 3. | Polar Capital Brian Ashford-Russell And Tim Woolley | 5,212,749 | $176,607,936 | +1% | 0.42% |
| 4. | Glenview Capital Larry Robbins | 5,081,091 | $172,147,363 | -24% | 3.13% |
| 5. | Millennium Management Israel Englander | 3,265,321 | $110,629,075 | +73% | 0.04% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.86 | 1,113 | $20,988.06 | 13,027 | 2025-09-05 | Filing | |
| $9.60 | 104,500 | $1,003,409.00 | 220,442 | 2019-06-04 | Filing | |
| $8.98 | 111,000 | $997,013.10 | 115,942 | 2019-06-03 | Filing | |
| $21.92 | 2,000 | $43,840.00 | 6,445 | 2018-08-03 | Filing | |
| $19.32 | 250,000 | $4,829,700.00 | 1,500,000 | 2018-05-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.57 | 18,600 | $680,291.28 | 25,591 | 2026-08-17 | Filing | |
| $34.87 | 17 | $592.71 | 73,247 | 2026-08-05 | Filing | |
| $34.88 | 12,827 | $447,350.60 | 6,774 | 2026-08-03 | Filing | |
| $34.88 | 25,578 | $892,050.65 | 134,877 | 2026-08-03 | Filing | |
| $32.19 | 9,989 | $321,546.91 | 0 | 2026-06-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 63,894,301 | $2,164,738,902 | 0.03% | |
| 2. | 42,933,367 | $1,454,582,474 | 9.94% | |
| 3. | 41,315,232 | $1,376,210,378 | 2.49% | |
| 4. | 39,854,383 | $1,350,266,496 | 5.27% | |
| 5. | 38,922,212 | $1,318,684,543 | 8.44% |
News See All
Is Teva Pharmaceutical Industries Limited (TEVA) Stock Undervalued After Recent Pullback and Vitiligo Program Update?
TheFly reported on June 18 that Jefferies analyst Dennis Ding maintained a Buy rating and a $40 price target on TEVA following recent share weakness.
12 Best Low-Priced Pharma Stocks to Buy Right Now
Investors looking for large returns without making a sizable initial commitment are still drawn to low-priced companies.
Is Teva Pharmaceutical Industries Limited (TEVA) Strengthening Its Neurology Portfolio With New Austedo Results?
TheFly reported on June 8 that TEVA announced new clinical and real-world findings supporting the use of Austedo and Austedo XR in patients with tardive dyskinesia.
10 Best Weight Loss Drug Stocks to Buy in 2026
The anti-obesity drug (AOM) market in the United States is rapidly changing structurally.
7 Best Pet Care Stocks to Buy for Consistent Recurring Revenue
The most durable cash flow in consumer markets may not come from subscriptions or software; it may come from the family dog.
8 Best Middle East and Africa Stocks to Buy According to Hedge Funds
The United States and Israel’s strikes on Iran have roiled global oil prices and reignited volatility across global financial markets.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2026 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2026 Earnings Call Transcript April 29, 2026Teva Pharmaceutical Industries Limited beats earnings expectations.
Is Teva Pharmaceutical Industries Limited (TEVA) A Good Stock To Buy Now?
Is TEVA a good stock to buy? We came across a bullish thesis on Teva Pharmaceutical Industries Limited on Kontra Investments’s Substack by Kontra.
Billionaire Druckenmiller and Jim Cramer Like These Stocks
Stanley Druckenmiller and Jim Cramer are two of the closely followed voices in financial markets. Though sometimes their stock preferences differ, they always draw widespread investor attention.
Hedge Fund Resource Center